AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Leukemia-Lymphoma, Adult T-CellHodgkin DiseaseLymphomaLeukemia, T-CellDeltaretrovirus InfectionsHuman T-lymphotropic virus 1LeukemiaLymphoma, T-CellDeltaretrovirusHTLV-I InfectionsLymphoma, B-CellLymphoma, Non-HodgkinT-LymphocytesGene Products, taxReed-Sternberg CellsLymphoma, Large B-Cell, DiffuseLeukemia, Myeloid, AcuteLeukemia, B-CellFlow CytometryParaparesis, Tropical SpasticBurkitt LymphomaLymphoma, FollicularHTLV-I AntibodiesAntigens, SurfaceInterleukin-2Leukemia, Lymphocytic, Chronic, B-CellLymphocyte ActivationLeukemia, LymphoidAntibodies, MonoclonalLeukemia, Prolymphocytic, T-CellCD4-Positive T-LymphocytesAntigens, CD27Leukocytes, MononuclearReceptors, Interleukin-2Leukemia, ExperimentalCell LineJurkat CellsLymphoma, T-Cell, PeripheralMolecular Sequence DataB-LymphocytesLymphoma, B-Cell, Marginal ZoneFetal BloodRNA, MessengerBase SequenceLymphoma, T-Cell, CutaneousCells, CulturedImmunophenotypingLymphocytesAntigens, CDT-Lymphocyte SubsetsPolymerase Chain ReactionPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Antigen, T-CellLeukemia, Myelogenous, Chronic, BCR-ABL PositivePrecursor T-Cell Lymphoblastic Leukemia-LymphomaLymphoma, Large-Cell, AnaplasticCell DivisionLymphoma, Mantle-CellPhenotypeCell Transformation, ViralLymph NodesLymphoma, AIDS-RelatedCarrier StateLeukemia Virus, MurineMice, TransgenicBone MarrowApoptosisInterferon-gammaGene Expression Regulation, LeukemicRetroviridae Proteins, OncogenicHerpesvirus 4, HumanTumor Cells, CulturedAntigens, CD30Antineoplastic Combined Chemotherapy ProtocolsCell Line, TumorThymus GlandClone CellsReceptors, ImmunologicCytokinesMice, SCIDCD8-Positive T-LymphocytesVincristineRemission InductionT-Lymphocytes, RegulatoryTime FactorsCell ProliferationHematopoietic Stem Cell TransplantationAntineoplastic AgentsProvirusesPrognosisReverse Transcriptase Polymerase Chain ReactionTreatment OutcomeMonocytesMice, Inbred BALB CImmunologic MemoryMice, Inbred C57BLSignal TransductionImmunohistochemistryCell DifferentiationAntigens, Neoplasm
Follicular lymphomaHodgkin'sCancersCutaneous T-Cell LMononuclearChronicMyelomaTumorsLymphocytesAggressiveMantle cell lymInternational Conference on Malignant LymphomaBurkittPatientsIncidence of leukaemia and lymphoma2023SubtypesDestroyed tissue anMalignanciesAnaplasticNeuroblastomaNeoplasmsChemotherapyCytotoxicLymphoproliferativeTumorOncologyDiffuseAutologousLymphaticStem cell transEtiologyMyelodysplasticPediatricMutationsImmuneTransplantationRelapseHematopoieticLymphoidUmbilical cordRemissionInvolvementClinicalCancerLymphoblastic leukemiaYoung adultsCD19Acute lymphoblaChildhood lymphomaPrognosticNeoplasmHeterogeneous
Follicular lymphoma2
  • Tazemetostat was studied in an open-label multicenter study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who received tazemetostat 800 mg twice daily. (targetedonc.com)
  • LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin's disease. (nih.gov)
Hodgkin's12
  • WM is a rare, slow-growing lymphoma that occurs in less than two percent of patients with non-Hodgkin's lymphoma (NHL) xi . (financialcontent.com)
  • Other conditions treated with stem cell transplants include sickle cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's sarcoma, desmoplastic small round cell tumor, chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. (wikipedia.org)
  • No HLA-matched (10/10 or 9/10) sibling donor or unrelated donor available NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. (knowcancer.com)
  • Hodgkin's disease, multiple myeloma (a cancer of the blood cells]. (echo23marines6569.org)
  • Diffuse large B cell lymphoma (DLBCL) represents the most frequent form of non-Hodgkin's lymphoma (NHL). (frontiersin.org)
  • Although significant strides have been made in the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL), major clinical advances have plateaued over despite the development of new chemotherapy regimens and strategies. (cancer.gov)
  • The Phase 1 clinical trial of KT-413 is designed to evaluate the safety, tolerability, PK/PD and clinical activity of KT-413 administered as an intravenous infusion once every 3 weeks to adult patients with relapsed and/or refractory B-cell non-Hodgkin's lymphomas. (pipelinereview.com)
  • CD19 is a protein expressed on the surface of B-cell-derived ALLs and non-Hodgkin's lymphomas. (medscape.com)
  • Broadly classified as either Hodgkin disease (Hodgkin's disease) or as non-Hodgkin lymphoma, lymphomas are clinically, pathologically, and biologically distinct (see the image below). (medscape.com)
  • For patient education information, see the Cancer Center , as well as Lymphoma (Hodgkin's Disease and Non-Hodgkin's Lymphoma) and Cancer of the Mouth and Throat . (medscape.com)
  • They point out that previous cases of pulmonary and disseminated nocardiosis have been associated with alemtuzumab treatment, but only in patients with preexisting conditions that compromise immunity, including non- Hodgkin's lymphoma, B cell lymphocytic leukemia, and organ transplantation. (medscape.com)
  • Cutaneous T-cell lymphoma is a general term from mycosis fungoides or occur spontane- to identify non-Hodgkin's T-cell lymphomas ously, although some authors now consider that primarily affect the skin. (bvsalud.org)
Cancers12
  • Lymphomas are cancers of the lymphatic system. (epnet.com)
  • These cancers are different from Hodgkin lymphoma . (epnet.com)
  • Non-Hodgkin lymphoma is not one disease but rather a category of lymphocyte cancers with a number of subgroups largely divided into aggressive and indolent types. (msdmanuals.com)
  • Non-Hodgkin lymphoma is the 2nd most common cancer in HIV-infected patients Non-Hodgkin lymphoma AIDS-defining cancers in patients infected with HIV are Kaposi sarcoma Lymphoma, Burkitt (or equivalent term) Lymphoma, immunoblastic (or equivalent term) Lymphoma, primary, of central nervous system read more , and some AIDS patients present with lymphoma. (msdmanuals.com)
  • It is most often performed for patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. (wikipedia.org)
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • We look forward to providing an update on the KT-333 Phase 1 clinical trial later this year, including initial evaluation of its antitumor activity in the target patient populations, and to working with the lymphoma community to rapidly advance this first-in-class heterobifunctional degrader in CTCL and PTCL in addition to exploring its potential in other cancers. (ozarksfirst.com)
  • This problems both peripheral cancers and bloodstream tissues, in which a neoplastic proliferation is normally accompanied by greater than the usual variety of regulatory lymphocytes. (cancer-pictures.org)
  • This fact sheet can help you understand how blood cancers and treatment for blood cancers can affect fertility. (schoolandyouth.org)
  • Facts 2019-2020 is an update of data available for blood cancers. (schoolandyouth.org)
  • This procedure is typically used to treat blood cancers such as leukemia, lymphoma, and multiple myeloma, as well as other disorders such as sickle cell anemia and thalassemia. (vanyahealth.com)
  • An interesting statistical association exists between high birth weight and the subsequent risk of childhood cancers, including non-Hodgkin lymphoma. (medscape.com)
Cutaneous T-Cell L4
  • WATERTOWN, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KT-333 for the treatment of R/R Cutaneous T-cell Lymphoma (CTCL) and R/R Peripheral T-cell Lymphoma (PTCL). (ozarksfirst.com)
  • Cutaneous T-cell lymphoma (CTCL) (see the image below) is a heterogeneous group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin, with no evidence of extracutaneous disease at the time of diagnosis. (medscape.com)
  • Early patch-stage cutaneous T-cell lymphoma. (medscape.com)
  • subtypes of cutaneous T-cell lymphoma, SS is a malignant neoplasm originating the most common of which are mycosis from T lymphocytes, which involves the fungoides and Sézary syndrome (SS). (bvsalud.org)
Mononuclear6
  • With DL4 still open to accrual at the time of the presentation, data reported from DL1-3 found plasma exposure increased with dose, reaching levels close to those predicted to be efficacious, and demonstrated dose-dependent STAT3 degradation with up to 88% mean maximum reduction in peripheral blood mononuclear cells and degradation profiles at DL3 near levels of knockdown that led to antitumor activity in preclinical models. (ozarksfirst.com)
  • T cell preparation: Patients and donors undergo apheresis to obtain peripheral blood mononuclear cells (PBMCs), which are expanded in culture. (knowcancer.com)
  • Human peripheral blood mononuclear cells (PBMC) were stained with FITC anti-human CD4 (clone RPA-T4, Cat. (bdbiosciences.com)
  • (C) Expressions of RNASET2 in 18 types of human blood cells and total peripheral blood mononuclear cells (PBMC) were analyzed in the Blood Atlas database. (frontiersin.org)
  • PD data in peripheral blood mononuclear cells (PBMC) demonstrated dose-dependent and sustained STAT3 degradation after dosing on Days 1 and 8, with mean maximum decrease of 66% in DL1 and 70% in DL2. (pipelinereview.com)
  • Besides eliminating circulating mononuclear cell subsets, alemtuzumab might have depleted lymphocytes in compartments (eg, intraepithelial lymphocytes) that are normally spared," they suggest. (medscape.com)
Chronic15
  • SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA) approved four applications for BRUKINSA (zanubrutinib), the company's Bruton's tyrosine kinase inhibitor (BTKi), including two Supplemental New Drug Applications for treatment-naïve adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and Waldenström's macroglobulinemia (WM), and two Supplemental Applications for conversions from conditional approval to regular approval. (financialcontent.com)
  • The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases. (news-medical.net)
  • The versatile drug is now also approved for the treatment of B-cell Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis in the adult population. (oncologynurseadvisor.com)
  • 5 however, it has been used to treat many pediatric hematologic conditions, including chronic immune thrombocytopenic purpura, posttransplant lymphoproliferative disease, juvenile rheumatoid arthritis, and other blood dyscrasias. (oncologynurseadvisor.com)
  • The apparent volume of distribution averaged 0.31 L/kg following a single 0.2 mg/kg oral dose of chlorambucil in 11 cancer patients with chronic lymphocytic leukemia. (nih.gov)
  • Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
  • This is a Phase I dose-finding study of FT596 as monotherapy and in combination with Rituximab or Obinutuzumab in subjects with relapsed/refractory B-cell Lymphoma or Chronic Lymphocytic Leukemia. (uchicagomedicine.org)
  • Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small. (uchicagomedicine.org)
  • This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic. (uchicagomedicine.org)
  • This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. (uchicagomedicine.org)
  • This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment. (uchicagomedicine.org)
  • NORTH CHICAGO, Ill. , May 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved VENCLEXTA® (venetoclax) in combination with obinutuzumab (GAZYVA®) for previously untreated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (abbvie.com)
  • The risk was significant for cases of non-Hodgkin lymphoma but not chronic lymphocytic leukaemia. (who.int)
  • To avoid immunosuppression in chronic lymphocytic leukaemia (CLL), there is an association between pesti- these patients all cases were selected non-Hodgkin lymphoma (NHL), cide exposure and lymphoproliferative before initiation of chemotherapy. (who.int)
  • Chronic Lymphocytic Leukemia (CLL) is also considered a subtype of NHL as it is essentially the same disease as Small Lymphocytic Lymphoma . (lymphoma.org.au)
Myeloma1
Tumors6
  • Overview of Lymphoma Lymphomas are a heterogeneous group of tumors arising in the reticuloendothelial and lymphatic systems. (msdmanuals.com)
  • The Phase 1 clinical trial of KT-333 is designed to evaluate the safety, tolerability, PK/PD and clinical activity of KT-333 dosed weekly in adult patients with relapsed and/or refractory lymphomas, leukemias and solid tumors. (ozarksfirst.com)
  • In June at the International Conference on Malignant Lymphoma (ICML), with a data cutoff date of May 1, 2023, Kymera presented data on thirteen patients who received a mean of five doses across the first four dose levels (DL1-4) of the trial, including patients with solid tumors, CTCL and PTCL. (ozarksfirst.com)
  • Leukemias, lymphomas and central nervous system tumors account for more than one half of new cancer cases in children. (aafp.org)
  • The most common childhood malignancies are acute lymphoblastic leukemia, central nervous system (CNS) tumors and lymphomas. (aafp.org)
  • Adoptive cellular therapy, especially chimeric antigen receptor (CAR) T cell therapy, has gained unprecedented success among hematologic tumors [ 11 ]. (hindawi.com)
Lymphocytes14
Aggressive8
  • With few exceptions, stem cell transplantation is usually reserved for patients with aggressive lymphomas after incomplete remission or relapse. (msdmanuals.com)
  • Lymphoblastic lymphoma is aggressive and progresses rapidly, presenting as stage IV disease in more than 70% of patients (see Staging). (medscape.com)
  • The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. (knowcancer.com)
  • The research interests of Joo Song, M.D., are focused on the genomics, prognostication, and classification of aggressive lymphomas such as Hodgkin lymphoma and diffuse large B cell lymphoma. (cityofhope.org)
  • Based on our results showing EPOCH to be effective and well tolerated, we began a phase II study of EPOCH in previously untreated patients with aggressive lymphomas. (cancer.gov)
  • We have recently developed and tested a "second generation" EPOCH regimen (EPOCH II) to replace stem cell transplant for lymphomas requiring high-dose intensity, including poor prognosis untreated aggressive lymphomas, potentially curable relapsed lymphomas, and low-grade lymphomas. (cancer.gov)
  • In our other co-lead program, NKX019, we continue to evaluate multiple strategies to treat patients with the most aggressive forms of lymphoma. (tmcnet.com)
  • Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols. (cdc.gov)
Mantle cell lym2
  • BRUKINSA previously received conditional approvals from NMPA for the treatment of adult patients with CLL/SLL and mantle cell lymphoma (MCL) who have received at least one prior therapy (R/R CLL/SLL and R/R MCL) in June 2020, and conditional approval for the treatment of adult patients with WM who have received at least one prior therapy (R/R WM) in June 2021. (financialcontent.com)
  • Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. (smw.ch)
International Conference on Malignant Lymphoma3
  • Interim phase II tazemetostat safety data were presented at the 14th International Conference on Malignant Lymphoma in June 2017. (targetedonc.com)
  • The data were shared in the online abstract book of the International Conference on Malignant Lymphoma (ICML), taking place from June 13-17, 2023, in Lugano, Switzerland, and reflect a data cut-off date of February 3, 2023. (pipelinereview.com)
  • In June 2023, Nkarta presented preliminary clinical data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 in patients with relapsed or refractory non-Hodgkin lymphoma (NHL) at two scientific meetings: an oral presentation at the annual meeting of the European Hematology Association (EHA) and an encore poster presentation at the International Conference on Malignant Lymphoma (17-ICML). (tmcnet.com)
Burkitt7
  • Using sporadic Burkitt lymphoma as our principle disease, we are studying the genetic, transcriptomic and clonal changes which occur in response to therapeutic pressure within patient-derived xenograft models. (ncl.ac.uk)
  • Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. (cdc.gov)
  • Identification of a novel variant of LMP-1 of EBV in patients with endemic Burkitt lymphoma in western Kenya. (cdc.gov)
  • Interleukin-6 and interleukin-10 gene promoter polymorphisms and risk of endemic Burkitt lymphoma. (cdc.gov)
  • Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma. (cdc.gov)
  • Genetic differences between paediatric and adult Burkitt lymphomas. (cdc.gov)
  • The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS. (cdc.gov)
Patients51
  • BRUKINSA has been recommended as the preferred regimen of multiple subtypes of lymphoma in both national and international guidelines i , ii , iii , iv , v . With these important approvals, BRUKINSA now becomes the only approved new-generation BTK inhibitor in China for the first-line treatment of adult CLL/SLL and WM patients, bringing healthcare providers in China with a new standard of care for their patients. (financialcontent.com)
  • In China, there are an estimated 88,200 patients diagnosed with lymphoma each year. (financialcontent.com)
  • Indeed, patients with non-Hodgkin lymphoma should generally be screened for HIV and hepatitis viruses. (msdmanuals.com)
  • Also, patients with a first-degree relative with Hodgkin or non-Hodgkin lymphoma have an increased risk of non-Hodgkin lymphoma. (msdmanuals.com)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • Naturally, more fit younger patients were able to receive more intensive conditioning regimens than less fit older adults. (ascopost.com)
  • Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced the initiation of a global phase III clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the treatment of newly diagnosed CD30-positive mature T-cell lymphoma (MTCL) patients, including patients with systemic anaplastic large cell lymphoma (sALCL) and other types of peripheral T-cell lymphomas. (news-medical.net)
  • Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy. (news-medical.net)
  • Non-ETP subtypes of T-cell lymphoblastic leukemia/lymphoma, in contrast, are associated with activating NOTCH1 mutations in over half of all patients and an additional 10% to 15% of cases have FBXW7 mutations, which also result in increased NOTCH signaling. (medscape.com)
  • Another interesting issue is a link between Treg ALL and cells among patients in the developmental age. (cancer-pictures.org)
  • Determine the feasibility and efficacy of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, melphalan, and thiotepa followed by allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies. (knowcancer.com)
  • Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients. (knowcancer.com)
  • Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo allogeneic PBSC transplantation on day 0. (knowcancer.com)
  • LMB-2 immunotoxin-treated, selectively-depleted donor T cells: Patients receive LMB-2 immunotoxin-treated, selectively-depleted donor T cells IV over 30-60 minutes on approximately day 28. (knowcancer.com)
  • Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
  • Chimeric antigen receptor T (CART) cell therapy targeting the B cell specific differentiation antigen CD19 has shown clinical efficacy in a subset of relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL) patients. (frontiersin.org)
  • Blood cell and serum markers, along with clinical data of DLBCL patients who were scheduled for CART cell therapy were evaluated to search for biomarkers predicting CART cell responsiveness. (frontiersin.org)
  • Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)
  • Twenty-six patients were infused with CART cells (median 81 days after leukapheresis) and were analyzed for the overall response (OR) 3 months later. (frontiersin.org)
  • Low frequency of differentiated CD3 + CD27 - CD28 - T cells at leukapheresis represents a novel pre-infusion blood biomarker predicting a favorable response to CART cell treatment in r/r DLBCL patients. (frontiersin.org)
  • The most common adverse event following allogeneic hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GVHD), which can increase morbidity and mortality in HSCT patients. (oncologynurseadvisor.com)
  • To date, no standard treatment is established for GVHD and no therapies are FDA approved for this indication in pediatric or adult patients. (oncologynurseadvisor.com)
  • Bivalirudin Cipla is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI. (medthority.com)
  • Bivalirudin Cipla is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention. (medthority.com)
  • This group etic stem cell transplant (HSCT) (8 allogeneic) and in 15 of patients has also been disproportionately represented patients with malignancy treated at 6 Australian tertiary cen- among those with severe infections from infl uenza A pan- ters during winter 2009. (cdc.gov)
  • In June 2023, Nkarta reported updated clinical data from its Phase 1 clinical trial evaluating NKX101 in patients with relapsed or refractory acute myeloid leukemia (AML). (tmcnet.com)
  • As of data cut-off on June 10, 2023, in patients that received the highest doses of NKX101 (3 weekly doses at 1 billion or 1.5 billion cells per dose) after fludarabine/cyclophosphamide (Flu/Cy) LD, 4 of 18 achieved CR/CRi (22% CR/CRi rate) and 3 of 18 achieved a complete response with hematologic recovery CR (17% CR rate). (tmcnet.com)
  • The update is expected to include additional patients treated with NKX101 at 1.5 billion cells/dose x 3 dose regimen following Flu/Ara-C LD, as well as longer-term follow up of patients who were in response as of the June 2023 data cut-off. (tmcnet.com)
  • Substrate reduction therapy (SRT) is an alternative treatment for appropriate adult patients with type 1 Gaucher disease. (medscape.com)
  • The results seen with the recently approved novel agent blinatumomab ( Blincyto , Amgen Inc) are "notable," say authors reporting a trial in which monotherapy produced complete remission in almost half of patients with relapses or refractory B-precursor acute lymphoblastic leukemia (ALL). (medscape.com)
  • A third of these patients subsequently underwent allogeneic hemopoietic stem cell transplantation. (medscape.com)
  • The drug was recently approved by the US Food and Drug Administration for patients with Philadelphia chromosome-negative precursor B-cell ALL who have relapsed or who were refractory to previous treatment. (medscape.com)
  • In an editorial published alongside the study, Xavier Thomas, MD, PhD, from the Hospices Civils de Lyon, Lyon-Sud Hospital, France, points out that many drugs have entered the marketplace, with the "potential to change the standard of care for adult patients with ALL. (medscape.com)
  • The study reported by Dr Topp and colleagues enrolled 189 patients with Philadelphia chromosome-negative, primary refractory or relapsed disease (first relapse within 12 months of first remission, relapse within 12 months after allogeneic hemopoietic stem cell transplantation, or no response to or relapse after first salvage therapy or beyond). (medscape.com)
  • Both haploidentical BMT and cord blood transplant are considered alternative options for patients who do not have a suitable matched donor. (vanyahealth.com)
  • Pembrolizumab (Keytruda), a humanized monoclonal anti-PD-1 antibody, is the first anti-PD-1 antibody approved by the FDA for the treatment of patients with unresectable or metastatic melanoma, non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, and gastric/gastroesophageal junction cancer [ 4 - 10 ]. (hindawi.com)
  • Adoptive cellular therapy transmits the sensitized T cells to patients with low cellular immune function, which helps patients obtain antitumor immunity. (hindawi.com)
  • In a multicenter, single-arm, open-label phase 2 study on patients with relapsed or refractory B-precursor acute lymphoblastic leukemia, the distribution of any grade neurologic ir-AEs frequency was 52% among patients receiving blinatumomab, and grade 3 or 4 neurologic ir-AEs occurred in 11% and 2% patients, respectively [ 19 ]. (hindawi.com)
  • Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. (uchicago.edu)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • We're particularly excited to be working with LLS TAP because it gives us access to their deep knowledge of blood cancer and their network of patients and drug development experts. (lls.org)
  • LLS TAP partnered with Stemline in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). (lls.org)
  • LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. (lls.org)
  • Since the late 1960s, treatment outcomes for pediatric patients with non-Hodgkin lymphoma have steadily improved. (medscape.com)
  • In a hospital-based, retrospective, case-control study in 20112012, adult cases of lymphoproliferative disorders (n = 130) were recruited from outpatient clinics in Menoufia, Egypt, while controls (n = 130) were age- and sex-matched fracture patients. (who.int)
  • The area of research for our group is malignant lymphomas - all possible aspects, aiming for the improvement of the quality of life and survival of these patients. (lu.se)
  • 2012, adult cases of lymphoproliferative disorders ( n = 130) were recruited from outpatient clinics in Menoufia, Egypt, while controls ( n = 130) were age- and sex-matched fracture patients. (who.int)
  • Il s'agit d'une étude transversale, monocentrique et descriptive, durant 12 mois, incluant les patients âgés d'au moins 18 ans admis en réanimation polyvalente pour un sepsis ou choc septique. (bvsalud.org)
Incidence of leukaemia and lymphoma2
  • ABSTRACT In view of the widespread use of pesticides in Egypt and the increasing incidence of leukaemia and lymphoma we aimed to assess pesticide exposure and other selected variables as risk factors for lymphoproliferative disorders (leukaemia and non-Hodgkin lymphoma). (who.int)
  • NK-cell lineages all of which are further incidence of leukaemia and lymphoma, and radiodiagnosis physician (for imag- classified as distinct entities including it is important to investigate whether ing). (who.int)
20232
  • Leukemia 2023, 37 (5), 988-1005. (ncl.ac.uk)
  • SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2023. (tmcnet.com)
Subtypes1
  • Although several subtypes of T-cell lymphoblastic leukemia/lymphoma exist, early T-cell precursor lymphoblastic leukemia (ETP-ALL) is the only subtype recognized as an entity in the revised 2016 WHO tumor classification. (medscape.com)
Destroyed tissue an1
  • The patient's own stored stem cells are then transfused into his/her bloodstream, where they replace destroyed tissue and resume the patient's normal blood-cell production. (wikipedia.org)
Malignancies4
  • These approvals further support BRUKINSA as the BTKi of choice in China for the treatment of B-cell malignancies such as CLL and WM," said Lai Wang, Ph.D., Global Head of R&D at BeiGene. (financialcontent.com)
  • BRUKINSA is a small molecule inhibitor of Bruton's tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. (financialcontent.com)
  • Designed to address both the IL-1R/TLR and Type 1 IFN pathways synergistically with a single molecule, KT-413 is in development for the treatment of MYD88-mutant B-cell malignancies. (pipelinereview.com)
  • Related studies have reported that the complete response rate of CD19-CAR-T cells in hematological malignancies is approximately 88-90% [ 13 , 14 ]. (hindawi.com)
Anaplastic1
  • B-cell LCLs and anaplastic (usually T-cell) LCLs (ie, Ki-1+ lymphomas) have come to be viewed as distinct entities. (medscape.com)
Neuroblastoma1
Neoplasms6
  • To complement The ASCO Post 's continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic transplantation for hematologic neoplasms in adults. (ascopost.com)
  • Lymphoblastic leukemias/lymphomas are neoplasms of precursor T cells and B cells or lymphoblasts. (medscape.com)
  • [ 1 ] ETP-ALL frequently has mutations in RUNX1 and/or ETV6 in addition to genes that are more commonly associated with myeloid neoplasms and are otherwise rare in T-cell lymphoblastic leukemia/lymphoma (such as FLT3 , IDH1/2 , TET2 , and DNMT3A mutations). (medscape.com)
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
  • Lymphomas are malignant neoplasms of lymphoid lineage. (medscape.com)
  • MYC rearranged B-cell neoplasms: Impact of genetics on classification. (cdc.gov)
Chemotherapy11
  • Chemotherapy involves the use of drugs to kill cancer cells. (epnet.com)
  • Large doses of chemotherapy and/or radiation therapy are then applied to kill the cancer cells. (epnet.com)
  • They are removed from circulating blood before chemotherapy or radiation treatment. (epnet.com)
  • The patient is then treated with high-dose chemotherapy with or without radiotherapy with the intention of eradicating the patient's malignant cell population at the cost of partial or complete bone marrow ablation (destruction of patient's bone marrow's ability to grow new blood cells). (wikipedia.org)
  • Chemotherapy, radiation, or both are initiated prior to transplantation to enable engraftment of the transplanted cells, decrease tumor size, and reduce immunoreactivity of the recipient. (oncologynurseadvisor.com)
  • An environment for GVHD is formed when antigen-presenting cells are activated by the patient's disease and the pretreatment destruction of cells caused by chemotherapy and radiotherapy. (oncologynurseadvisor.com)
  • This is an important study, and ultimately, I think our goal is to overcome the use of chemotherapy and radiation, which can destroy healthy cells along with malignant ones," commented Catherine Bollard, MD, MBChB, a bone and marrow transplant specialist at George Washington University/Children's National Medical Health System, Washington, DC. (medscape.com)
  • In this type of transplant, the patient's own stem cells are collected before the high-dose chemotherapy and/or radiation therapy is given. (vanyahealth.com)
  • After the chemotherapy and radiation therapy, the stored stem cells are thawed and returned to the patient's body. (vanyahealth.com)
  • This type of transplant is used when the patient's own cells are not damaged or diseased, but are being used as a rescue therapy after high-dose chemotherapy or radiation therapy. (vanyahealth.com)
  • It is essential to identify and initiate treatment early with chemotherapy and/or radiation therapy in all cases of nodal or visceral (including neural) involvement with lymphoma. (researchgate.net)
Cytotoxic6
  • Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)
  • In vitro , CD3 + CD8 + CD27 - CD28 - compared to CD3 + CD8 + CD27 + CD28 + CART cells displayed similar CD19 + target cell-specific cytotoxicity, but were hypoproliferative and produced less cytotoxic cytokines (IFN-γ and TNF-α). (frontiersin.org)
  • Cytotoxic T cells mount a response on the body and target recipient cells are lysed. (oncologynurseadvisor.com)
  • When CD20 antagonists decrease the amount of circulating B cells, the body may not produce as many cytotoxic T cells that can potentially induce GVHD. (oncologynurseadvisor.com)
  • Blinatumomab is the first of a novel class of drugs known as bispecific T-cell engagers and is designed to direct cytotoxic T cells to CD19-expressing cancer cells. (medscape.com)
  • Immune checkpoint inhibitors (ICIs) are antibodies that target crucial signaling pathways, such as programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), to improve the activation of T cells and enhance the immune response to cancer cells. (hindawi.com)
Lymphoproliferative2
  • Many investigators have suggested that both lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) may be part of one clinical spectrum of a single malignant lymphoproliferative disorder . (medscape.com)
  • Also, the term "primary cutaneous CD4 + small/medium T-cell lymphoma" was changed to "primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. (medscape.com)
Tumor9
  • Radiation is directed at the tumor from a source outside the body to kill the cancer cells. (epnet.com)
  • They interfere with the division of cancer cells and can slow tumor growth. (epnet.com)
  • CAR-expression on T or NK cells allows them to specifically target cancer cells via recognition of tumor associated antigens. (nature.com)
  • The addition of separate adapter molecules (AMs) specific for tumor antigens and CAR-immune cells targeting these AMs allows a more precise and temporally limited therapy. (nature.com)
  • 2 EZH2 has also been implicated in tumor initiation and progression, migration, angiogenesis, stem cell self-renewal, and activated T-regulatory cell functioning. (targetedonc.com)
  • The scientific symptoms of the condition and the best therapeutic effect rely on the natural characteristics from the tumor cell. (cancer-pictures.org)
  • He is also utilizing multi-immunofluorescence to study the tumor microenvironment in lymphomas to better understand the dynamics and interactions of the cellular subsets and correlate with response to therapies. (cityofhope.org)
  • In vitro , overexpression of the mdr-1 gene product, P-glycoprotein (Pgp), in tumor cells can confer high-level resistance to natural product-derived cytotoxics-anthracyclines, vinca alkaloids, epipodophyllotoxins, and taxanes. (cancer.gov)
  • In contrast, an extramedullary tumor accompanied by marrow involvement below this threshold constitutes stage 4 lymphoma. (medscape.com)
Oncology2
  • Inside our research, we looked into a people of Compact disc4+Compact disc25highCD127low/CFoxP3+ regulatory T cells in the bone tissue marrow and peripheral bloodstream of kids with severe lymphoblastic leukemia treated in HAS1 the Section of Pediatrics, Oncology and Hematology, Medical School of Gdansk in 2011C2016. (cancer-pictures.org)
  • I am also currently revising chapters on childhood lymphoma and tumour lysis syndrome for the second edition of the Oxford University Handbook of Paediatric Haematology and Oncology. (ncl.ac.uk)
Diffuse2
Autologous6
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • Autologous HSCT requires the extraction (apheresis) of hematopoietic stem cells (HSCs) from the patient and storage of the harvested cells in a freezer. (wikipedia.org)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. (nature.com)
  • An autologous CAR-T or NK cell therapy comprises several steps as shown in Fig. 1 . (nature.com)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
Lymphatic7
  • Two-sided color chart with information about blood cells and the lymphatic system that can be used by healthcare professionals as a patient education tool. (schoolandyouth.org)
  • They mostly live in our lymphatic system with only very few found in our blood. (lymphoma.org.au)
  • Because they live mostly in our lymphatic system, lymphoma often does not show up on blood tests. (lymphoma.org.au)
  • Our lymphatic system is responsible for cleaning our blood of toxins and waste products and includes our lymph nodes, spleen, thymus, tonsils, appendix and a fluid called lymph. (lymphoma.org.au)
  • Lymphomas have been called cancer of the blood, cancer of the lymphatic system and cancer of the immune system. (lymphoma.org.au)
  • Lymphoma usually starts in your lymphatic system, but occasionally can start in other parts of your body. (lymphoma.org.au)
  • Understanding your lymphatic and immune systems will help you understand lymphoma a little easier. (lymphoma.org.au)
Stem cell trans3
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. (uchicagomedicine.org)
Etiology2
  • In industrialized countries, most individuals with non-Hodgkin lymphoma have no known etiology or association. (medscape.com)
  • The epidemiologic association between non-Hodgkin lymphoma and certain paternal occupations (eg, those that increase contact with other individuals) suggests a possible infective etiology for childhood non-Hodgkin lymphoma. (medscape.com)
Myelodysplastic3
Pediatric1
  • Candidates for HSCTs include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia with defective stem cells, and also children or adults with aplastic anemia who have lost their stem cells after birth. (wikipedia.org)
Mutations4
  • Normally, potentially malignant cells are continuously eliminated by the immune system, but cancer cells can accumulate certain mutations, which allow them to escape these mechanisms [ 2 ]. (nature.com)
  • A variety of cancer types exhibit chromatin-modifying mutations, which often correlate with cell fate decisions. (targetedonc.com)
  • The origin and evolution of mutations in acute myeloid leukemia. (smw.ch)
  • EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. (cdc.gov)
Immune18
  • They performed pre-clinical studies utilizing a mouse model and characterized changes in immune cells and pancreatic β cells leading to checkpoint inhibitor-induced diabetes. (yale.edu)
  • To learn more about their methods and analysis, read "Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes " in JCI Insight . (yale.edu)
  • Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes. (yale.edu)
  • Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. (nature.com)
  • Cancer immunotherapies aim to support or boost the patient's immune system to enable the effective clearance of cancer cells. (nature.com)
  • One way to achieve this is to genetically modify immune cells, mainly T cells and recently also natural killer (NK) cells, to express chimeric antigen receptors (CARs). (nature.com)
  • Furthermore, the so-called adapter CARs have been developed by splitting antigen recognition and CAR-immune cell activation. (nature.com)
  • CAR-modified immune cells are expanded until sufficient cell numbers are attained and are adoptively transferred into the patient to fight malignant cells. (nature.com)
  • Prior to infusion of the CAR-modified immune cells, lymphodepletion is performed in most therapeutic settings to allow efficient cell engraftment [ 10 ]. (nature.com)
  • Residual nonmalignant T cells and B cells are in permanent cell-to-cell contact with lymphoblasts and are involved in active immune responses [2]. (cancer-pictures.org)
  • I also work closely with UK and European colleagues (iBFM, EICNHL, ESID) to develop our understanding of development of lymphoid malignancy in children with inherited immune deficiency or DNA repair disorders and provide the paediatric clinical service for Langerhans cell histiocytosis and collaborate with Newcastle Human Dendritic Cell Laboratory ( http://www.hudendritic.org/ ) run by Professor Matt Collin. (ncl.ac.uk)
  • An important component is the study of immune modulation with IL-2 and peripheral blood stem cells (PBSC) on the generation of natural killer (NK) and lymphokine-activated killer cells (LAK), immune recovery, and eradication of microscopic disease posttherapy. (cancer.gov)
  • This enzyme is detected in all tissues, especially in embryonic tissues and immune cells ( https://www.proteinatlas.org/ ) ( Figures 1B,C ). The full-length human RNase T2 has 256 amino acids (AA) and a predicted size of 29 kD ( Table 1 ). (frontiersin.org)
  • The evolutionary conservation structure of RNase T2 and distribution of RNASET2 in human tissues and immune cells. (frontiersin.org)
  • This strategy, along with others, is harnessing our immune system to target cancer cells. (medscape.com)
  • However, blinatumomab's dependence on circulating immune cells may limit the ability to combine it with myelosuppressive therapies, Dr Thomas notes. (medscape.com)
  • The main advantage is that cord blood cells are less mature than adult stem cells, which makes it less likely for the patient's immune system to reject the transplant. (vanyahealth.com)
  • T-cells that can fight infection directly and recruit other immune cells. (lymphoma.org.au)
Transplantation13
  • Hematopoietic stem-cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived from bone marrow, peripheral blood, or umbilical cord blood in order to replicate inside of a patient and to produce additional normal blood cells. (wikipedia.org)
  • In 2006, 50,417 first HSCTs were recorded worldwide, according to a global survey of 1,327 centers in 71 countries conducted by the Worldwide Network for Blood and Marrow Transplantation. (wikipedia.org)
  • The Worldwide Network for Blood and Marrow Transplantation reported the millionth transplant to have been undertaken in December 2012. (wikipedia.org)
  • In 2014, according to the World Marrow Donor Association, stem-cell products provided for unrelated transplantation worldwide had increased to 20,604 (4,149 bone-marrow donations, 12,506 peripheral blood stem-cell donations, and 3,949 cord-blood units). (wikipedia.org)
  • 1 After transplantation, donor T cells are activated by antigen-presenting cells. (oncologynurseadvisor.com)
  • Bone Marrow Transplantation (BMT) is a medical procedure that involves replacing damaged or diseased bone marrow with healthy bone marrow stem cells. (vanyahealth.com)
  • To reduce the risk of these complications, special techniques are used to purify the donor's stem cells before transplantation. (vanyahealth.com)
  • Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
Relapse1
  • Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. (smw.ch)
Hematopoietic4
  • Eosinophils are derived from hematopoietic stem cells initially committed to the myeloid line and then to the basophil-eosinophil granulocyte lineage. (medscape.com)
  • Cord blood is a rich source of hematopoietic stem cells, which can develop into all the different types of blood cells. (vanyahealth.com)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • The marrow specimen showed extensive replacement of normal hematopoietic elements by immature monocytic cells. (contemporarypediatrics.com)
Lymphoid3
  • Non-Hodgkin lymphomas are a heterogeneous group of disorders involving malignant monoclonal proliferation of lymphoid cells in lymphoreticular sites, including lymph nodes, bone marrow, the spleen, the liver, and the gastrointestinal tract. (msdmanuals.com)
  • 1. Launch Acute lymphoblastic leukemia (ALL), the most frequent childhood cancer, is certainly a heterogeneous disease occurring because of the malignant clonal proliferation of lymphoid progenitors [1]. (cancer-pictures.org)
  • In contrast, non-Hodgkin lymphoma is best regarded as a systemic disease, because of the unique anatomy of the lymphoid system and because of the physiology of lymphoid cells, which tend to migrate whether they are normal or malignant. (medscape.com)
Umbilical cord1
Remission2
  • It was showed previously that raised percentages and elevated suppressor properties of Treg cells are observed even after achieving a remission and after completing the treatment of AML [6]. (cancer-pictures.org)
  • Minimal residual disease (MRD) refers to the small number of malignant cells that remain after therapy when the patient is in remission and shows no symptoms or overt signs of disease. (smw.ch)
Involvement5
  • Most lymphomas are nodal with variable involvement of the bone marrow and peripheral blood. (msdmanuals.com)
  • In large cell lymphoma and leukemia cells involvement of body fluid this concept becomes less challenging. (cytojournal.com)
  • Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. (cityofhope.org)
  • FDG-PET/CT is the standard of care in lymphoma staging, restaging, and therapy response assessment, but has an inherent limitation in the detection of disease involvement in the central nervous system. (researchgate.net)
  • the case for its involvement in childhood non-Hodgkin lymphoma is less compelling than the case for adults, but this is still under investigation. (medscape.com)
Clinical8
  • In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany. (nature.com)
  • I am an MRC Clinician Scientist and Honorary Consultant Paediatric Oncologist, providing a clinical service for young people with lymphoma or Langerhans cell histiocytosis at the Great North Children's Hospital, Newcastle. (ncl.ac.uk)
  • This regimen is based on experimental/clinical observations that suggest infusion schedules may improve the therapeutic index of natural product-derived cytotoxics, and that high-dose alkylator therapy can overcome drug resistance in lymphoma. (cancer.gov)
  • Nkarta is evaluating the potential for clinical development of NKX019 in non-malignant, B-cell mediated disease. (tmcnet.com)
  • Currently, there are over 20 active clinical studies with TAP-supported therapies, including several registration-enabling clinical studies in blood cancer. (lls.org)
  • Newer therapies that target immunologic and biologic aspects of the lymphoma are still under development but beginning to appear in the clinical arena. (medscape.com)
  • 2. Clinical epidemiology - using data from the Swedish Lymphoma Registry to provide clinically useful real world data on treatment and prognosis, in many cases in collaboration with Nordic colleagues. (lu.se)
  • Initial management consisted of en una paciente con topical corticosteroids and oral antihistamines with little clinical response. (bvsalud.org)
Cancer13
  • Cancer occurs when cells in the body divide out of control or order. (epnet.com)
  • They will kill mostly cancer cells. (epnet.com)
  • As in normal stem cells, EZH2 is highly expressed in cancer stem cell populations and suppresses differentiation via repression of lineage-specific factors to maintain these populations. (targetedonc.com)
  • ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults. (news-medical.net)
  • This bilingual English/Spanish palm card includes information about financial assistance for individuals with blood cancer. (schoolandyouth.org)
  • This fact sheet provides information about minimal residual disease (MRD), which refers to the small number of cancer cells that remain in the body after treatment. (schoolandyouth.org)
  • This fact sheet provides general information about choosing a blood cancer specialist or treatment center. (schoolandyouth.org)
  • Together with Dr Chris Bacon I run the Lymphoma Research Group within the Wolfson Childhood Cancer Research Centre and collaborate closely with Prof Vikki Rand at the National Horizon's Centre, Teesside University. (ncl.ac.uk)
  • I lecture on Cancer Stem Cells, Heterogeneity and Evolution within the Biomedical Sciences undergraduate degree programme. (ncl.ac.uk)
  • TAP is LLS' Mission-driven, strategic venture philanthropy initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care. (lls.org)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. (lls.org)
  • Lymphoma is The most common cancer in adolescents and young adults, the 3rd most common in children less than 14 years, and the 6th most common cancer of all people of all ages. (lymphoma.org.au)
  • Uneétude descriptive, transversale portant sur les patientes traitées en radiothérapie à l'Hôpital Général de Douala pour cancer du col de l'utérus a été réalisée d'octobre 2020 à janvier 2021.Résultats. (bvsalud.org)
Lymphoblastic leukemia9
  • The U.S. Food and Drug Administration today approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL). (news-medical.net)
  • however, because lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) are known to represent the same disease entity, the World Health Organization (WHO) classification has unified these entities as precursor B-cell and T-cell lymphoblastic leukemia/lymphoma. (medscape.com)
  • T-lymphoblastic lymphoma (T-LBL) accounts for 25-30% of childhood NHL and is closely related to T-lymphoblastic leukemia (T-ALL). (medscape.com)
  • Population-based attributes for Social Exclusion Index (SEI) and household size may be useful surrogate markers of early exposure to childhood infections, which has been found to decrease the risk of acute lymphoblastic leukemia (ALL). (medscape.com)
  • Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. (smw.ch)
  • Campana D. Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? (smw.ch)
  • Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. (smw.ch)
  • Subjects with Philadelphia Chromosome positive acute lymphoblastic leukemia (Ph+ALL) subjects are eligible if they progressed, had stable disease or relapsed after two lines of therapy, including tyrosine kinase inhibitors (TKIs). (who.int)
  • Therefore, these entities (acute lymphoblastic leukemia and lymphoblastic lymphoma) are best considered in terms of a spectrum ranging from clinically localized disease to overt leukemia. (medscape.com)
Young adults1
  • Lymphoblastic lymphoma is associated with exposure to radiation or pesticides and congenital or acquired immunosuppression and is more common in children and young adults. (medscape.com)
CD193
  • CD3 + CD8 + T cells outperformed CD3 + CD4 + T cells 3- to 6-fold in terms of their ability to kill CD19 + target cells. (frontiersin.org)
  • Blinatumomab is a bispecific T-cell engager (BiTE) targeting CD19 on malignant B cells and CD3 on normal host T cells. (hindawi.com)
  • Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (who.int)
Acute lymphobla1
  • The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related variations (0.53 at 45-54 years, ∼1.0 at 55-74 years and 1.45 at 75-99 years). (medscape.com)
Childhood lymphoma1
  • Other, less common forms of childhood lymphoma (some of which are much more common in adults) are not discussed. (medscape.com)
Prognostic1
Neoplasm2
  • Epithelioid angiosarcoma is a rare malignant neoplasm found in vascular endothelial cells. (bvsalud.org)
  • A dermatology work-up was initiated, and the síndrome de Sézary initial diagnosis of malignant T-cell neoplasm was confirmed. (bvsalud.org)
Heterogeneous1
  • Despite this heterogeneous response, blood pre-infusion biomarkers predicting responsiveness to CART cell therapy are currently understudied. (frontiersin.org)